Feline Gastrointestinal Adenocarcinoma Study Guide

Overview and Clinical Importance

Gastrointestinal adenocarcinoma is the second most common intestinal neoplasm in cats after lymphoma, representing 20-35% of all feline GI tumors. These are highly aggressive, locally invasive malignancies with high metastatic potential that typically affect older cats (mean age greater than 10 years). The prognosis is generally poor despite aggressive treatment, making early recognition and appropriate staging critical for NAVLE success.

Epidemiology and Risk Factors

Age and Breed Predisposition

Feline intestinal adenocarcinoma predominantly affects geriatric cats with a mean age of 10-12 years at diagnosis. Siamese and other Asian breeds (Tonkinese, Burmese) appear overrepresented, accounting for approximately 14% of cases in some studies, suggesting a possible genetic predisposition. Male cats may have a slightly higher incidence, though this is inconsistent across studies.

Anatomic Distribution

Pathophysiology and Tumor Behavior

Growth Pattern and Local Invasion

Feline GI adenocarcinomas exhibit characteristic annular, stenosing growth that encircles the intestinal lumen circumferentially, causing progressive luminal narrowing and mechanical obstruction. The tumors demonstrate transmural invasion through all intestinal layers with frequent extension through the serosa. Serosal infiltration occurs in approximately 85-87% of cases, often associated with carcinomatosis (peritoneal seeding), which is present in 81% of surgical cases.

The tumor growth leads to muscular hypertrophy and hyperplasia in unaffected intestinal segments proximal to the obstruction as the bowel attempts to overcome the stenosis. This compensatory response can be palpable on abdominal examination and visible on imaging.

Metastatic Behavior

High metastatic rate: Feline intestinal adenocarcinomas are biologically aggressive with metastatic rates of 55-76% at diagnosis. Common metastatic sites include regional mesenteric lymph nodes (52% of cases), liver, lungs (up to 20%), and peritoneum. Lymphatic and vascular invasion are frequently identified histologically, facilitating systemic spread.

Carcinomatosis occurs when tumor cells seed the peritoneal cavity, forming multiple small nodules on serosal surfaces and mesentery. This often produces malignant ascites and carries a grave prognosis. The peritoneal spread pattern makes complete surgical resection nearly impossible.

Clinical Presentation

Signalment and History

Cats with GI adenocarcinoma typically present with a chronic, progressive history of nonspecific gastrointestinal signs lasting weeks to months. Owners often report gradual deterioration despite symptomatic treatment. The insidious onset can delay diagnosis, allowing tumor progression and metastasis.

Clinical Signs

Physical Examination Findings

Palpable abdominal mass: Approximately 35-40% of cats have a palpable mass on abdominal examination. The mass is typically firm, non-mobile, and may be tubular or nodular. Palpation sensitivity is limited by body condition, tumor location, and patient temperament.

Body condition: Most cats present with poor body condition (BCS 2-3 out of 9) and evidence of chronic disease including muscle wasting, dehydration, and unkempt haircoat. Weight loss often exceeds 15-20% of normal body weight.

Other findings: Abdominal fluid wave may be detected if ascites is present. Rectal examination may reveal a palpable mass in cases of colorectal adenocarcinoma. Peripheral lymph nodes are typically normal unless systemic metastasis has occurred.

Diagnostic Approach

Clinical Pathology

Hematology: Nonregenerative anemia is common (PCV often 20-30%), resulting from chronic disease and occult GI blood loss. Neutrophilia with or without left shift may occur secondary to inflammation or tumor necrosis. Thrombocytosis can develop as an acute phase response.

Serum biochemistry: Hypoalbuminemia (albumin less than 2.5 g/dL) occurs in approximately 50% of cases due to protein-losing enteropathy, malabsorption, and negative acute phase response. Hyperglobulinemia may be present from chronic inflammation. Prerenal azotemia can develop from dehydration. Electrolyte disturbances (hypokalemia, hypochloremia) may occur with chronic vomiting.

Fecal examination: Occult blood is frequently positive. Fecal floatation should be performed to rule out parasitism as a differential diagnosis.

Diagnostic Imaging

Radiography

Survey abdominal radiographs demonstrate abnormalities in approximately 60-70% of cases but are relatively nonspecific. Findings include gas-distended bowel loops proximal to obstruction, loss of abdominal detail (suggesting effusion), and occasionally a visible soft tissue mass. The classic gravel sign - accumulation of mineral-opaque particulate material in retained, desiccated ingesta - may be visible in chronic partial obstruction.

Contrast radiography with barium can demonstrate strictures, filling defects, and delayed transit but has largely been replaced by ultrasound as the primary imaging modality.

Ultrasonography

Abdominal ultrasound is the most sensitive imaging modality for detecting intestinal masses, identifying tumors in 89% of cases. Characteristic ultrasonographic features include:

• Mass appearance: Segmental, circumferential bowel wall thickening (often greater than 5-8 mm) with transmural loss of normal wall layering. The mass typically appears heterogeneous to hypoechoic with mixed echogenicity.

• Distribution: Usually solitary and focal, unlike lymphoma which can be multifocal or diffuse.

• Secondary findings: Mechanical ileus (dilated bowel proximal to mass), reduced intestinal motility, regional lymphadenopathy (often greater than 5 mm), peritoneal effusion (16-27% of cases).

Differentiating adenocarcinoma from lymphoma: Adenocarcinoma typically shows mixed echogenicity, solitary focal disease, and mechanical obstruction. Lymphoma more commonly appears hypoechoic, may be multifocal, and less commonly causes mechanical obstruction. However, definitive differentiation requires histopathology.

Cytology and Histopathology

Fine Needle Aspiration Cytology

Ultrasound-guided fine needle aspiration (FNA) of intestinal masses has limited diagnostic accuracy in feline intestinal adenocarcinoma, with cytologic-histopathologic agreement in only 45% of cases. The most common cause of discordance is marked inflammation obscuring neoplastic cells in cytology samples.

Cytologic findings: When diagnostic, FNA reveals moderately to markedly atypical epithelial cells in clusters or individually. Cells have oval nuclei with coarse chromatin, prominent nucleoli (often multiple), and scant basophilic cytoplasm. Moderate anisocytosis and anisokaryosis are typical. Binucleated and multinucleated cells may be present. Concurrent inflammation (neutrophils, macrophages) is common.

Histopathology

Histopathologic examination of surgical or endoscopic biopsies provides definitive diagnosis and prognostic information. Tumors are classified according to WHO criteria based on predominant growth pattern and degree of differentiation.

Key histologic features: Regardless of subtype, neoplastic cells are irregularly cuboidal to columnar with moderate eosinophilic cytoplasm and varying degrees of vacuolization and goblet cell differentiation. Moderate to marked anisokaryosis with aberrant nuclear shapes, prominent nucleoli, and 1-8 mitotic figures per high-power field are typical.

Invasion patterns: Transmural invasion extending through submucosa, muscularis, and serosa is characteristic. Lymphatic invasion is present in many cases. Metaplastic bone formation can occur in approximately 4% of cases, particularly in mucinous subtypes.

Immunohistochemistry

Immunohistochemical staining helps confirm epithelial origin and classify tumors. Feline intestinal adenocarcinomas are typically positive for cytokeratin 20 (CK20) in 100% of cases and CDX2 in 96% of cases. Focal positivity for CD10 (22%) and CK7 (30%) may occur. These markers help differentiate adenocarcinoma from other tumor types, particularly lymphoma and mesenchymal tumors.

Staging and Prognostic Factors

Complete staging is essential before treatment planning and includes thoracic radiographs (three-view), complete abdominal ultrasound, and evaluation of regional lymph nodes. Advanced imaging (CT) can better delineate tumor extent and detect distant metastases but is not always necessary.

Treatment

Surgical Management

Wide surgical excision with intestinal resection and anastomosis is the primary treatment for feline intestinal adenocarcinoma. Surgical goals include achieving wide margins (ideally 3 cm orad and aborad of the tumor), removing affected regional lymph nodes, and assessing for metastatic disease.

Margin assessment: Complete intestinal transection margins are achievable in 94% of cases. However, complete mural margins (tumor-free intestinal wall at the site of tumor attachment) are obtained in only 15% of cases due to the circumferential, infiltrative nature of these tumors. Incomplete mural margins do not preclude surgery as they may still provide palliation and improved survival versus no surgery.

Surgical procedures by location:

• Small intestinal masses: Resection and end-to-end anastomosis

• Ileocecocolic junction masses: Ileocolic anastomosis with removal of cecum

• Colonic masses: Subtotal colectomy (removal of majority of colon)

Surgical outcomes: Modern perioperative care has dramatically improved surgical survival compared to historical reports. Cats that survive to discharge have median survival times of 5-15 months for small intestinal tumors and 4.5-9 months for colonic tumors. Median survival for cats undergoing surgery is 284-365 days versus only 22 days for those not receiving surgery.

Adjuvant Chemotherapy

The role of chemotherapy in feline intestinal adenocarcinoma remains incompletely defined. Recent studies have not demonstrated a significant survival benefit with adjuvant chemotherapy, though this may reflect the aggressive biology of the disease and small sample sizes. Chemotherapy is most commonly recommended for colonic adenocarcinoma and cases with documented metastasis.

Combined protocols: Some oncologists use alternating carboplatin and doxorubicin to potentially maximize efficacy through different mechanisms of action and minimize cross-resistance. Combination with NSAIDs (particularly piroxicam) may provide additional benefit through COX-2 inhibition but requires careful monitoring for toxicity.

Palliative and Supportive Care

Nutritional support: Esophagostomy or gastrostomy tube placement should be considered for cats with severe weight loss or anorexia to maintain body condition during treatment.

Pain management: Multimodal analgesia including opioids (buprenorphine, fentanyl patches), gabapentin, and cautious NSAID use for visceral pain.

Antiemetics: Maropitant (1 mg/kg SQ/PO q24h), ondansetron, or metoclopramide for nausea and vomiting control.

Stent placement: Colonic stenting has been reported for palliation of colonic obstruction when surgery is declined or not feasible. This is an advanced procedure with limited availability.

Prognosis

Overall prognosis for feline intestinal adenocarcinoma is guarded to poor due to the aggressive biological behavior, high metastatic rate, and frequent presence of advanced disease at diagnosis.

Negative prognostic factors:

• High mitotic count (most consistently significant)

• Presence of distant metastasis (lung, liver)

• Nodal metastasis (particularly in colonic tumors)

• Carcinomatosis

• Poor differentiation

• Mucinous histologic subtype

Positive prognostic factors:

• Tubular/well-differentiated histology

• Absence of gross metastasis at surgery

• Low mitotic activity

• Surgical resection versus no treatment

Differential Diagnoses

When evaluating a geriatric cat with chronic gastrointestinal signs and weight loss, consider:

1. Alimentary lymphoma: Most common feline intestinal neoplasm. Can be low-grade (small cell) or high-grade (large cell). Low-grade lymphoma causes diffuse thickening of intestinal wall (particularly muscularis) with preserved layering. High-grade lymphoma can mimic adenocarcinoma with focal masses and loss of layering. Definitive diagnosis requires histopathology and immunohistochemistry.

2. Inflammatory bowel disease (IBD): Chronic inflammation can cause wall thickening and clinical signs similar to neoplasia. IBD typically causes more diffuse disease and may preserve wall layering better than neoplasia. Endoscopic biopsy can differentiate, but full-thickness surgical biopsy is often needed for definitive diagnosis.

3. Intestinal mast cell tumor: Can present as focal hypoechoic masses at duodenum, jejunum, ileocecocolic junction, or colon. May have diffuse wall thickening pattern. Diagnosis requires cytology or histopathology with special stains.

4. Gastrointestinal stromal tumor (GIST): Mesenchymal tumor that can occur in stomach or intestines. Typically appears as hypoechoic mass. Immunohistochemistry (positive for CD117/c-kit) differentiates from adenocarcinoma.

5. Chronic pancreatitis: Can cause duodenal thickening and similar clinical signs. Feline pancreas-specific lipase (fPL) and ultrasound findings of pancreatic changes help differentiate.

6. Foreign body: Linear foreign bodies can cause intestinal plication. Acute obstruction from non-linear foreign bodies can mimic tumor. History and radiographic/ultrasonographic findings (gravel sign, plication) help differentiate.